Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1)

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

July 4, 2017

Primary Completion Date

May 31, 2019

Study Completion Date

December 31, 2021

Conditions
Carcinoma, Non-small-cell LungMesotheliomaPancreatic Neoplasms
Interventions
DRUG

Defactinib

cross reference with arm/group descriptions

DRUG

Pembrolizumab

cross reference with arm/group descriptions

Trial Locations (5)

BT9 7BL

RECRUITING

Belfast Health and Social Care Trust, Cancer Centre, Lisburn Road, Belfast

EH4 2XR

RECRUITING

Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh

G12 0YN

RECRUITING

Beatson West of Scotland Cancer Centre, Glasgow

LE2 7LX

RECRUITING

Department of Cancer Studies, University of Leicester, Leicester Royal Infirmary, Leicester

SO16 6YD

RECRUITING

Cancer Research UK Centre, Southampton University Hospitals and University of Southampton, Southampton

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

University of Glasgow

OTHER

collaborator

Cancer Research UK

OTHER

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

Verastem, Inc.

INDUSTRY

collaborator

University of Edinburgh

OTHER

collaborator

University of Southampton

OTHER

collaborator

University of Leicester

OTHER

collaborator

Queen's University, Belfast

OTHER

lead

NHS Greater Glasgow and Clyde

OTHER